Repositioning of Lansoprazole as a Protective Agent Against Cisplatin-Induced Ototoxicity.

Wakai, Eri; Ikemura, Kenji; Mizuno, Toshiro; Takeuchi, Kazuhiko; Tamaru, Satoshi; Okuda, Masahiro; Nishimura, Yuhei

Wakai, Eri; Ikemura, Kenji; Mizuno, Toshiro; Takeuchi, Kazuhiko; Tamaru, Satoshi; Okuda, Masahiro; Nishimura, Yuhei.

Afiliación

Wakai E; Department of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu, Japan.
Ikemura K; Department of Pharmacy, Osaka University Hospital, Suita, Japan.
Mizuno T; Department of Medical Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Takeuchi K; Department of Otorhinolaryngology-Head and Neck Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
Tamaru S; Clinical Research Support Center, Mie University Hospital, Tsu, Japan.
Okuda M; Department of Pharmacy, Osaka University Hospital, Suita, Japan.
Nishimura Y; Department of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu, Japan.

Front Pharmacol ; 13: 896760, 2022.

Article en En | MEDLINE | ID: mdl-35910376

Palabras clave

adverse event; cisplatin; electronic health record; genome editing; organic cation transporter 2; ototoxicity; proton pump inhibitor; zebrafish

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google